This is the translation of the text you provided:
This invention relates to a method for preparing a novel 7H-pyrrolo[2,3-d]pyrimidine-4-thiol derivative or a pharmaceutically acceptable salt thereof and pharmaceutical compositions containing it as an active ingredient. Compositions containing the novel 7H-pyrrolo[2,3-d]pyrimidine-4-thiol derivative according to the present invention can be useful for the prevention or treatment of diseases induced by the overactivity of Janus kinase (JAK).
[EN] PROCESSES FOR MAKING PRMT5 INHIBITORS<br/>[FR] PROCÉDÉS DE FABRICATION D'INHIBITEURS DE PRMT5
申请人:PRELUDE THERAPEUTICS INC
公开号:WO2022125735A1
公开(公告)日:2022-06-16
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.
7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds
申请人:WARNER-LAMBERT COMPANY
公开号:EP0057548A2
公开(公告)日:1982-08-11
7-β-D-arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine, its hydroxy, amino and sulfhydryl derivatives, corresponding esters and non-toxic pharmaceutically acceptable salts are disclosed. Such compounds may be produced by arabinofura- nosylation of the requisite heterocyclic compound, with 2,3,5-tri-O-benzyl-a-D-arabinofuranosyl halide and further reaction to obtain the desired compound. These water-soluble compounds are resistant to adenosine deaminase and exhibit antiviral activity.
Seela, Frank; Steker, Herbert, Liebigs Annalen der Chemie, 1984, # 10, p. 1719 - 1730
作者:Seela, Frank、Steker, Herbert
DOI:——
日期:——
Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage
申请人:Sem Daniel S.
公开号:US20100305326A1
公开(公告)日:2010-12-02
Disclosed herein are methods related to drug development. The methods typically include steps whereby two chemical fragments are identified as binding to a target protein and subsequently the two chemical fragments are joined to create a new chemical entity that binds to the target protein.
SCN9A ANTISENSE OLIGONUCLEOTIDES
申请人:OliPass Corporation
公开号:US20190218255A1
公开(公告)日:2019-07-18
The current invention provides peptide nucleic acid derivatives targeting a part of the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce splice variants of the SCN9A mRNA in cells, and are useful to safely treat pains or conditions involving Na
v
1.7 activity.